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Abstract:  Artemisinin-combination  therapies  (ACTs)  are  recommended  for  the  treatment  of 
uncomplicated  malaria  in  endemic  areas  with  multidrug  resistant 
report  a  case  of  possible  artemether
uncomplicated P. falciparum malaria imported from Democratic Republic of Congo.
Many  studies  have  reported  artemisinin
combination  therapies  (ACTs)  to  be  the  best 
antimalarial drugs available, due to their efficacy and 
potential to lower the emergence of resistance.
are  recommended  by the  World  Health Organization 
(WHO) for the treatment of uncomplicated malaria in 
endemic  areas  with  multidrug  resistant 
falciparum.
3
A  32-year  old  Caucasian  man,  two  days  after 
coming  back  from  one  month  travel  business
Democratic  Republic  of Congo,  was  admitted to  the 
Infectious  Diseases  Unit  because  of  high  fever, 
headache, nausea and epigastric pain started 48 hours 
before. He had not taken any prophylaxis for malaria. 
Upon admission patient's vital parameters were: body 
temperature  37,1°C,  pulse  rate  112/minute,  blood 
pressure 120/60 mm Hg, peripheral oxygen saturation 
99%.  Blood test  results are  summarized in 
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combination  therapies  (ACTs)  are  recommended  for  the  treatment  of 
uncomplicated  malaria  in  endemic  areas  with  multidrug  resistant  Plasmodium  falciparum
report  a  case  of  possible  artemether-lumefantrine  clinical  failure  in  an  Italian  traveler  with 
malaria imported from Democratic Republic of Congo.
Many  studies  have  reported  artemisinin-
combination  therapies  (ACTs)  to  be  the  best 
al drugs available, due to their efficacy and 
potential to lower the emergence of resistance.
1,2 ACTs 
are  recommended  by the  World  Health Organization 
(WHO) for the treatment of uncomplicated malaria in 
endemic  areas  with  multidrug  resistant  Plasmodium 
year  old  Caucasian  man,  two  days  after 
travel  business in 
Democratic  Republic  of Congo,  was  admitted to  the 
Infectious  Diseases  Unit  because  of  high  fever, 
headache, nausea and epigastric pain started 48 hours 
efore. He had not taken any prophylaxis for malaria. 
Upon admission patient's vital parameters were: body 
temperature  37,1°C,  pulse  rate  112/minute,  blood 
pressure 120/60 mm Hg, peripheral oxygen saturation 
99%.  Blood test  results are  summarized in  Table  1.
Peripheral blood smear was positive for 
falciparum  with  0,2% parasitemia.  Chest  X
electrocardiogram were normal. The combination drug 
Riamet® (arthemeter-lumefantrine 20/120 mg), bought 
in  Switzerland,  was  started  following  manufacture
advice: 6 dose regimen of 4 tablets at 0, 6, 18, 30, 42, 
54 hours after meals. Within 48 hours the patient was 
afebrile and blood smear was negative for Plasmodium. 
The  patient  was  discharged  after  72  hours  in  good 
clinical condition. After 14 days he wa
the Infectious Diseases unit with high fever (39.6 °C) 
and headache, started 48 hours before. Laboratory tests 
showed  mild  leukocytosis  and  anemia:  hepatic 
enzymes  were  substantially  similar  to  his  previous 
values.
Laboratory  tests  are  show
cultures  were  done  using  the  BacT/ALERT  system 
(bioMérieux®,  Marcy  l’Etoile,  France)  and  blood 
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combination  therapies  (ACTs)  are  recommended  for  the  treatment  of 
Plasmodium  falciparum.  We 
lumefantrine  clinical  failure  in  an  Italian  traveler  with 
malaria imported from Democratic Republic of Congo.
Peripheral blood smear was positive for Plasmodium 
with  0,2% parasitemia.  Chest  X-Ray  and 
electrocardiogram were normal. The combination drug 
lumefantrine 20/120 mg), bought 
in  Switzerland,  was  started  following  manufacturer 
advice: 6 dose regimen of 4 tablets at 0, 6, 18, 30, 42, 
54 hours after meals. Within 48 hours the patient was 
afebrile and blood smear was negative for Plasmodium. 
The  patient  was  discharged  after  72  hours  in  good 
clinical condition. After 14 days he was readmitted to 
the Infectious Diseases unit with high fever (39.6 °C) 
and headache, started 48 hours before. Laboratory tests 
showed  mild  leukocytosis  and  anemia:  hepatic 
enzymes  were  substantially  similar  to  his  previous 
Laboratory  tests  are  shown  in  Table  1. Blood 
cultures  were  done  using  the  BacT/ALERT  system 
(bioMérieux®,  Marcy  l’Etoile,  France)  and  blood Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
smear  was  performed  and  resulted  positive  for 
Plasmodium  falciparum  with  2%  parasitemia.  The 
combination of oral quinine solfate 600 mg three times 
per  day  and  doxycicline 100  mg  twice  per  day  was 
started and continued for 7 days. He was discharged 
after  48  hours  and  completed  the  combination 
treatment  without  adverse  events.  Blood  cultures  for 
bacteria  and  fungi  were  negative.  A  control  of 
biochemical tests and blood smear done after 2 days 
showed  resolution  of  anemia  and  negativity  of 
parasitemia.  The  patient  did  not  report  other  febrile 
episodes.
Table 1. Pre-treatment blood results.
Admission 1 Admission 2
Leucocytes 4,8*10
3/μ l 7,9*10
3/μ l
Erythrocytes 5,39*10
6/μ l 4,3*10
6/μ l
Hemoglobin 16,9 g/dl 13,4 g/dl
Hematocrit 50,7% 38,9%
Platelets 130*10
3/μ l 272*10
3/μ l
AST 75 U/l 39 U/l
ALT 111 U/l 59 U/l
LDH 554 U/l 339 U/l
γ-GTP 227 U/l 200 U/l
Total bilirubin 2,29 mg/dl 1,45 mg/dl
Creatinine 0,95 mg/dl 0,72 mg/dl
C-reactive protein 13,7 mg/dl 2,3 mg/dl
AST: aspartate amino transferase; ALT: alanine amino transferase; 
LDH: lactic dehidrogenase; γ-GTP: gamma glutamil transpeptidase.
The association of arthemeter-lumefantrine is one of 
the most popular ACTs and is currently used in many 
countries: it is an effective blood schizonticidal drug, it 
is  well tolerated and fast acting.
4 Arthemeter rapidly 
reduces the parasite mass and resolves the symptoms 
while  lumefantrine  eliminates  residual  parasites. The 
efficacy  of  the  combination  mostly  depends  in  the 
number  of  parasites  remaining  after  arthemeter  has 
been  eliminated  from  the  body  and  the  duration  of 
which lumefantrine plasma concentration exceeds the 
minimum inhibitor concentration against the parasites. 
No problems with absorption of arthemeter has been 
reported  while  co-administration  with  fatty  food 
ensures  maximum  absorption  of  lumefantrine 
component
5  and  the  wide  variation  in  the 
pharmacokinetics of lumefantrine among individuals is 
known  to  influence  the  efficacy  of  artemether-
lumefantrine combination. 
We  report  a  case  of  possible  clinical  failure  of 
artemether-lumefantrine  in  an  Italian  traveler  with 
imported  uncomplicated  Plasmodium  falciparum 
malaria.  To  our  knowledge one  previous  case  of 
treatment  failure  of  artemether-lumefantrine  in 
Plasmodium falciparum malaria imported from Sierra 
Leone  has  been  published  so  far.
6 The  authors 
hypothesized  that  this  was  due  to  low  plasma 
concentration  of  lumefantrine  component  for  its 
assumption without meals. 
The  combination  drug  artemether-lumefantrine  is 
highly effective in Africa and published data indicated 
a good efficacy in Democratic Republic of Congo.
7-8
Nonetheless  falciparum  recrudescence  after  ACTs 
were recently increasingly reported
8-10 and high failure 
rates were seen in Cambodia (13,5% in 2006), where 
the emergence of lumefantrine resistance could not be 
excluded  and  could  be  explained  by  the  cross 
resistance between mefloquine and lumefantrine.
According  to  WHO  classification  of  treatment 
outcome in high-transmission areas (2009) our patient 
must  be  considered  a  late  clinical  failure.  Our 
laboratory  could  not  perform  either  an  in  vitro 
antimalarial  susceptibility  test  or  to  measure  blood 
antimalarial levels so the association therapy with oral 
quinine and doxycicline was chosen in the suspicion of 
inefficacy of the combination artemether-lumefantrine. 
Two  hypothesis  were  made:  the  first  was  that  the 
patient’s second episode was a re-infection rather than 
a  recrudescence,  being  infected  twice  over  14  days 
before  his  return.  As  the  association  of  artemether-
lumefantrine  is  ineffective  against  exo-erytrocytic 
cycle, the first course treatment could have cured first 
malaria episode but could have been partially effective 
for the incubating Plasmodium. The second hypothesis 
was a recrudescence due to low plasma concentration 
of lumefantrine for an unrecognized patient’s defect in 
intestinal  absorption  rather  than  an  incorrect  drug 
assumption (in fact the patient properly took each dose 
after meal). 
With  increasing  number  of  travelers  into  malaria 
endemic  areas  more  attention  should  be  paid  in 
advising the patients to consult health practitioners if 
fever  reappears  after  a  full  course  of  antimalarial 
treatment,  to  early  diagnose  recrudescences  or  re-
infections.
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